PureTech Health plc (FRA:0VQ)

Germany flag Germany · Delayed Price · Currency is EUR
1.400
0.00 (0.00%)
At close: Nov 28, 2025
-29.29%
Market Cap343.11M
Revenue (ttm)5.44M
Net Income (ttm)43.15M
Shares Outn/a
EPS (ttm)0.17
PE Ratio7.95
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume500
Open1.400
Previous Close1.400
Day's Range1.400 - 1.400
52-Week Range1.160 - 2.180
Betan/a
RSI49.24
Earnings DateNov 28, 2025

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 56
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0VQ
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.